Preclinical study reveals proton pump inhibitor effects on palbociclib and ribociclib pharmacokinetics in rats, highlighting mechanisms involving cytochrome P450 and P-glycoprotein.
Numerous clinical concerns have been expressed regarding the potential worsening of cyclin-dependent kinase 4/6 inhibitor effects in breast cancer patients because of co-administration of proton pump inhibitors. Hence, this study evaluated the effects of proton pump inhibitors on the pharmacokinetics of palbociclib and ribociclib in terms of cytochrome P450 (CYP) 3A4 and P-glycoprotein involvement.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: